Centre Hospitalier Epicura
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Centre Hospitalier Epicura in Ath is conducting research in cardiovascular disease focused on acute ischemic stroke and high-risk transient ischemic attack. The studies are designed to evaluate whether new treatment approaches can better prevent recurrent stroke and improve protection after a recent cerebrovascular event.
- Testing a new therapy to reduce the risk of ischemic stroke
- Studying treatment options for people after a high-risk transient ischemic attack
- Assessing whether prevention strategies can improve outcomes after stroke
This work reflects a strong interest in improving stroke prevention and supporting safer, more effective care for patients at risk of further vascular events.
Hemic and Lymphatic Diseases
Clinical research at this site also covers hemic and lymphatic diseases, with studies in multiple myeloma and diffuse large B-cell lymphoma. These trials are exploring new treatment combinations and comparing them with established options to improve disease control and patient outcomes.
- Evaluating new therapies for relapsed or refractory multiple myeloma
- Comparing treatment approaches in newly diagnosed multiple myeloma
- Testing improved options for relapsed or refractory diffuse large B-cell lymphoma
The research aims to find more effective and better-tolerated treatments for challenging blood cancers, with attention to both response and overall treatment benefit.
Neoplasms
In the field of neoplasms, the site is studying locally advanced rectal cancer and related cancer treatment strategies. The trials are assessing how different pre-surgical and combined treatment approaches may improve the balance between effectiveness and safety, especially in older patients.
- Comparing treatment strategies for locally advanced rectal cancer
- Evaluating approaches that may improve the trade-off between cancer control and safety
- Supporting better treatment planning before surgery
These studies aim to refine rectal cancer care by identifying options that may offer strong results while reducing treatment burden.
Kidney Disease Research
Although the main therapeutic categories are broader, the trial portfolio at Centre Hospitalier Epicura also includes chronic kidney disease. This research is focused on improving kidney-related outcomes by examining whether new treatment options can lower urine albumin and better support standard care.
- Studying a new therapy for chronic kidney disease
- Measuring changes linked to kidney damage and disease progression
- Evaluating whether treatment can improve renal protection alongside standard care
The goal is to advance kidney disease management through therapies that may help preserve kidney function and reduce long-term risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Epicura
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 3 | Unknown | 2024-02-07 | 2025-04-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.